Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report

Author： Markman M.   Iseminger K.A.   Hatch K.D.   Creasman W.T.   Barnes W.   Dubeshter B.  

Publisher： Academic Press

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.62, Iss.1, 1996-07, pp. : 4-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

By Markman M.   Blessing J.A.   Moore D.   Ball H.   Lentz S.S.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 226-229

Elsevier

Access to resources Recommend Favorite

Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial

By Markman M.   Blessing J.A.   DeGeest K.   Morgan M.   Look K.Y.   Herzog T.J.   Rose P.G.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 444-446

Elsevier

Access to resources Recommend Favorite

Phase II Trial of CI-958 in Recurrent Platinum-Refractory Ovarian Carcinoma - A Gynecologic Oncology Group Study

By Hoffman M.A.   Blessing J.A.   Morgan M.  

Gynecologic Oncology, Vol. 79, Iss. 3, 2000-12 ,pp. : 463-465

Elsevier

Access to resources Recommend Favorite

Evaluation of Recombinant Human Interleukin-12 in Patients with Recurrent or Refractory Ovarian Cancer: A Gynecologic Oncology Group Study

By Hurteau J.A.   Blessing J.A.   DeCesare S.L.   Creasman W.T.  

Gynecologic Oncology, Vol. 82, Iss. 1, 2001-07 ,pp. : 7-10

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Plaxe S.C.   Blessing J.A.   Bookman M.A.   Creasman W.T.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 32-35

Elsevier

Access to resources Recommend Favorite